新华财经北京12月10日电（胡晨曦）科创50指数12月10日早间低开，指数早盘持续调整，午后指数有所 反弹，尾盘时短暂翻红但力度不强，最终以微跌报收。至收盘时，科创50指数报1346.7点，跌幅 0.03%，指数振幅为2.45%，总成交额约553.6亿元。 12月10日，科创综指全日收涨0.14%，收于1604.56点，总成交额1803亿元。 个股表现方面，不考虑上市首日的百奥赛图，霍莱沃涨停，涨幅居首；佳华科技跌10.1%，跌幅居首。 成交额方面，摩尔线程成交额108.2亿元，位居首位；汉邦科技成交额731.4万元，位居末位。 换手率方面，不考虑上市首日的百奥赛图，摩尔线程换手率为51.93%，位居首位；中复神鹰换手率为 0.14%，位居末位。 （文章来源：新华财经） 从盘面来看，科创板595只个股涨少跌多，高价股表现分化，低价股则多数下跌。细分领域来看，半导 体股、通信设备股表现强势，电气设备股、软件服务股跌幅靠前；专用机械股表现分化。 百奥赛图12月10日在上交所科创板上市，公司证券代码为688796，发行价格26.68元／股，发行市盈率 为519.12倍。百奥赛图是一家主要从事药物开发业务及临床前研究 ...

Core Viewpoint - The article discusses the upcoming IPO of Bai'ao Saitou on the Sci-Tech Innovation Board, highlighting its market position, financial performance, and future growth prospects [2][3]. Company Overview - Bai'ao Saitou is one of the first companies in China to enter the gene editing field, establishing itself as a leader in the model organism sector [2]. - The company has partnerships with the top ten global pharmaceutical companies based on projected 2024 revenues [2]. Financial Performance - The total market value of Bai'ao Saitou is 10.66 billion yuan, with an issuance price of 26.68 yuan per share and a high price-to-earnings ratio of 519.12 [2]. - The company reported revenue of 980 million yuan in 2024, reflecting a year-on-year growth of 36.76%, with previous years showing revenues of 717 million yuan in 2023 (+34.28%) and 534 million yuan in 2022 (+50.58%) [3]. Business Segmentation - The company's revenue composition includes: - Antibody development business: 26.23% - Model organism sales: 44.20% - Preclinical pharmacology and efficacy evaluation: 24.97% [2][3]. Fundraising Purpose - The funds raised from the IPO will be directed towards the construction of an early drug research and development service platform, antibody drug development, and to supplement working capital [3].